RADNOR, PA /ACCESSWIRE/May 1, 2022/ The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) advises investors that the company has filed a securities class action lawsuit against Natera, Inc. (“Natera”) NTRA on behalf of all persons and entities who purchased or otherwise acquired shares of Natera common stock between February 26, 2020 and April 19, 2022 inclusive (the “Class Period”).
CLICK HERE TO SUBMIT YOUR NATERA LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE INTO YOUR BROWSER: https://www.ktmc.com/new-cases/natera-inc?utm_source=PR&utm_medium=link&utm_campaign=natera&mktm=r
CAN’T SEE THIS VIDEO? PLEASE CLICK HERE
TO SEE OUR COMPLAINT, PLEASE CLICK HERE
PRINCIPAL APPLICANT DEADLINE: JUNE 27, 2022
COURSE PERIOD: FROM FEBRUARY 26, 2020 to APRIL 19, 2022
CONTACT A LAWYER TO DISCUSS YOUR RIGHTS: James Maro, Esq. (484) 270-1453 or Email at [email protected]
Kessler Topaz is one of the world’s foremost advocates for protecting the public from corporate fraud and other wrongdoing. Our securities fraud litigants are consistently individually recognized as leaders in the field and our firm is both feared and respected within the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the categories of shareholders we represent.
NATERA’S ALLEGED MISCONDUCT
Natera, a Delaware company with principal executive offices in Austin, Texas, offers genetic testing in the areas of women’s health, oncology and organ health. Among other things, the Company produces and markets a non-invasive prenatal test (NIPT), called “Panorama”, and a screening test for kidney transplant failure, called “Prospera”. Throughout the class action period, the defendants repeatedly assured investors that Panorama was reliable, that Prospera was more accurate than competing tests, and that Natera’s growth was driven by its superior technology and customer experience.
Investors, however, began to learn the truth on January 1, 2022, when The New York Times published a detailed report questioning the accuracy of some prenatal tests manufactured by Natera and other diagnostic test companies. Among others, The New York Times reported that positive Natera results for several genetic disorders were incorrect more than 80% of the time. On this news, Natera’s common stock price fell $5.35 per share, or approximately 6% over two trading days, from a close of $93.39 per share on December 31, 2021 to 88, $04 per share on January 4, 2022.
Less than two weeks later, on January 14, 2022, the Campaign for Accountability – a nonprofit watchdog group – filed a complaint with the United States Securities and Exchange Commission asking for an investigation into whether Natera has repeatedly claimed — in marketing materials and earnings calls — that its tests are much more reliable than they appear. On this news, Natera’s common stock price fell $6.29 per share, or more than 9%, from a close of $67.37 per share on January 14, 2022 to $61.08 per share. on January 18, 2022.
Then, on March 9, 2022, Hindenburg Research released an investigative report alleging, among other things, that “Natera’s revenue growth was fueled by deceptive sales and billing practices targeting physicians, insurance companies and pregnant women”. On this news, Natera’s common stock price fell $28.65 per share, or more than 52%, from a close of $54.75 per share on March 8, 2022 to an intraday low of 26, $10 per share on March 9. , 2022.
Several days later, on March 14, 2022, a jury found that Natera intentionally and deliberately misled the public by using false advertisements to market Prospera in violation of federal and state laws. Among other things, the jury found that Natera’s marketing incorrectly claimed that Prospera was more accurate than competing kidney transplant tests offered by CareDx, Inc. Ultimately, the jury awarded CareDx, Inc. 44, $9 million in damages. On this news, Natera common stock fell $8.81 per share, or about 22.5%, from an intraday high of $39.13 per share on March 14, 2022, to close at 30.32. $ per share on March 15, 2022.
Finally, on April 19, 2022, the U.S. Food and Drug Administration (FDA) released a safety communication “to educate patients and healthcare providers and to help reduce the inappropriate use of [NIPTs]. The FDA has warned that statements about the reliability and accuracy of NIPTs “may not be supported by strong scientific evidence” and disclosed “cases where a screening test has reported a genetic abnormality and a confirmatory diagnostic test later found the fetus to be healthy.” The FDA has suggested that patients discuss the benefits and risks with a healthcare professional before deciding to undergo NIPT or making any related decisions. to pregnancy based on NIPT results. Additionally, the FDA has advised healthcare professionals not to rely on NIPT results alone to diagnose chromosomal abnormalities or disorders. As a result of this news, the course of Natera common stock fell as low as $1.53 per share, or about 3.9%, from an intraday high of $39.63 per share on April 19, 2022, to close at $38.10 per share. action on April 20, 2022.
The Complaint alleges that, throughout the Class Period, Defendants misrepresented and/or failed to disclose that: (1) Panorama was unreliable and resulted in high false positive rates; (2) Prospera did not have superior accuracy compared to competitive tests; (3) as a result of defendants’ false and misleading claims regarding Natera’s technology, the company was exposed to substantial legal and regulatory risks; (4) Natera relied on deceptive sales and billing practices to drive revenue growth; and (5) as a result of the foregoing, defendants’ statements about the company’s business, operations and prospects lacked a reasonable basis.
WHAT CAN I DO?
Natera investors can no later than June 27, 2022seek to be appointed as the lead plaintiff representing the class through Kessler Topaz Meltzer & Check, LLPor another attorney, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Natera investors who have suffered significant losses to contact the company directly for more information.
CLICK HERE TO REGISTER FOR THE CASE
WHO CAN BE A PRINCIPAL APPLICANT?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead applicant is usually the investor or small group of investors who have the greatest financial interest and who are also adequate and typical of the category of investors proposed. The lead plaintiff chooses an attorney to represent the lead plaintiff and the class and those attorneys, if approved by the court, are the lead or class attorneys. Your ability to participate in any collection is not affected by whether or not to serve as lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP pursues class action lawsuits in state and federal courts nationwide and around the world. The company has developed a worldwide reputation for excellence and has recovered billions of dollars for victims of fraud and other malpractice. All of our work is guided by a common goal: to protect investors, consumers, employees and others from fraud, abuse, corporate and fiduciary misconduct and negligence. For more information on Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
THE SOURCE: Kessler Topaz Meltzer & Check, LLP
See the source version on accesswire.com: